Cancer Application: Search Trigger Cancer Receptors

Two types of enrichment analyses were designed using hypergeometric test, receptor downstream interaction partner enrichment and receptor downstream pathway elements enrichment. When either downstream interaction partners or pathway elements are enriched with cancer related annotation, the upstream mediating receptor may be a Cancer-triggering receptor.

Statistics of Significant Receptor

Cancer NameReceptor Numbers (Pairs) *Receptor Numbers (Path)**
Adrenal Gland Neoplasms 94
Biliary Tract Cancer 7
Brain Cancer 8
Breast Cancer 14 2
Central Nervous System Neoplasms 11 20
Colorectal Cancer 11 95
Esophageal Cancer 6
Gastric Cancer 5 1
Head and Neck Cancer 90 260
Hepatocellular Carcinoma 8 34
Intestines Cancer 10 104
Leukemia 9 5
Lung Cancer 19 109
Lymphoma 7 113
Melanoma 22
Myeloproliferative Disorders 3
Neoplasms by Histologic Type 26 96
Non-small cell lung carcinoma 5
Oral Cancer 7
Oral Premalignant Lesions 1
Other Cancer 7
Ovarian Cancer 17 9
Pancreatic Cancer 29
Pituitary Carcinoma 46
Prostate Cancer 5
Renal Cancer 4
Sarcoma 7
Skin Cancer 18
Small cell lung carcinoma 2
Testicular Cancer 61
Thyroid Carcinoma 14 43
Urinary Bladder Cancer 5
Uterine Cancer 5
acute lymphocytic leukemia 6
acute myeloid leukemia 6
breast ductal carcinoma 4
chronic lymphocytic leukemia 8
chronic myeloid leukemia 1
follicular thyroid carcinoma 3
hepatitis B virus 8
hepatitis C virus 12
pancreatic ductal adenocarcinoma 1
papillary thyroid carcinoma 7
*Receptor Numbers (Pairs): significant receptor number (p-value <= 0.05, enrichment anlysis of receptor mediated direct interaction pairs in one cancer type).
**Receptor Numbers (Path): significant receptor number (p-value <= 0.05, enrichment anlysis of receptor mediated shortest path in one cancer type).